Yue Li1, Ashley Duche1, Michael R Sayer1, Don Roosan2, Farid G Khalafalla3, Rennolds S Ostrom1, Jennifer Totonchy1, Moom R Roosan4. 1. School of Pharmacy, Chapman University, Irvine, CA, 92618, USA. 2. College of Pharmacy, Western University of Health Sciences, Pomona, CA, 91766, USA. 3. College of Pharmacy, California Health Sciences University, Clovis, CA, 93612, USA. 4. School of Pharmacy, Chapman University, Irvine, CA, 92618, USA. roosan@chapman.edu.
Abstract
BACKGROUND: The ongoing COVID-19 outbreak has caused devastating mortality and posed a significant threat to public health worldwide. Despite the severity of this illness and 2.3 million worldwide deaths, the disease mechanism is mostly unknown. Previous studies that characterized differential gene expression due to SARS-CoV-2 infection lacked robust validation. Although vaccines are now available, effective treatment options are still out of reach. RESULTS: To characterize the transcriptional activity of SARS-CoV-2 infection, a gene signature consisting of 25 genes was generated using a publicly available RNA-Sequencing (RNA-Seq) dataset of cultured cells infected with SARS-CoV-2. The signature estimated infection level accurately in bronchoalveolar lavage fluid (BALF) cells and peripheral blood mononuclear cells (PBMCs) from healthy and infected patients (mean 0.001 vs. 0.958; P < 0.0001). These signature genes were investigated in their ability to distinguish the severity of SARS-CoV-2 infection in a single-cell RNA-Sequencing dataset. TNFAIP3, PPP1R15A, NFKBIA, and IFIT2 had shown bimodal gene expression in various immune cells from severely infected patients compared to healthy or moderate infection cases. Finally, this signature was assessed using the publicly available ConnectivityMap database to identify potential disease mechanisms and drug repurposing candidates. Pharmacological classes of tricyclic antidepressants, SRC-inhibitors, HDAC inhibitors, MEK inhibitors, and drugs such as atorvastatin, ibuprofen, and ketoconazole showed strong negative associations (connectivity score < - 90), highlighting the need for further evaluation of these candidates for their efficacy in treating SARS-CoV-2 infection. CONCLUSIONS: Thus, using the 25-gene SARS-CoV-2 infection signature, the SARS-CoV-2 infection status was captured in BALF cells, PBMCs and postmortem lung biopsies. In addition, candidate SARS-CoV-2 therapies with known safety profiles were identified. The signature genes could potentially also be used to characterize the COVID-19 disease severity in patients' expression profiles of BALF cells.
BACKGROUND: The ongoing COVID-19 outbreak has caused devastating mortality and posed a significant threat to public health worldwide. Despite the severity of this illness and 2.3 million worldwide deaths, the disease mechanism is mostly unknown. Previous studies that characterized differential gene expression due to SARS-CoV-2 infection lacked robust validation. Although vaccines are now available, effective treatment options are still out of reach. RESULTS: To characterize the transcriptional activity of SARS-CoV-2 infection, a gene signature consisting of 25 genes was generated using a publicly available RNA-Sequencing (RNA-Seq) dataset of cultured cells infected with SARS-CoV-2. The signature estimated infection level accurately in bronchoalveolar lavage fluid (BALF) cells and peripheral blood mononuclear cells (PBMCs) from healthy and infectedpatients (mean 0.001 vs. 0.958; P < 0.0001). These signature genes were investigated in their ability to distinguish the severity of SARS-CoV-2 infection in a single-cell RNA-Sequencing dataset. TNFAIP3, PPP1R15A, NFKBIA, and IFIT2 had shown bimodal gene expression in various immune cells from severely infectedpatients compared to healthy or moderate infection cases. Finally, this signature was assessed using the publicly available ConnectivityMap database to identify potential disease mechanisms and drug repurposing candidates. Pharmacological classes of tricyclic antidepressants, SRC-inhibitors, HDAC inhibitors, MEK inhibitors, and drugs such as atorvastatin, ibuprofen, and ketoconazole showed strong negative associations (connectivity score < - 90), highlighting the need for further evaluation of these candidates for their efficacy in treating SARS-CoV-2 infection. CONCLUSIONS: Thus, using the 25-gene SARS-CoV-2 infection signature, the SARS-CoV-2 infection status was captured in BALF cells, PBMCs and postmortem lung biopsies. In addition, candidate SARS-CoV-2 therapies with known safety profiles were identified. The signature genes could potentially also be used to characterize the COVID-19 disease severity in patients' expression profiles of BALF cells.
Authors: Christelle D Douillet; William P Robinson; Peter M Milano; Richard C Boucher; Preston B Rich Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-04-21 Impact factor: 5.464
Authors: Marco Idzko; Stefan Dichmann; Davide Ferrari; Francesco Di Virgilio; Andrea la Sala; Giampiero Girolomoni; Elisabeth Panther; Johannes Norgauer Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-07-17 Impact factor: 91.245
Authors: Lena F Schimke; Alexandre H C Marques; Gabriela Crispim Baiocchi; Caroline Aliane de Souza Prado; Dennyson Leandro M Fonseca; Paula Paccielli Freire; Desirée Rodrigues Plaça; Igor Salerno Filgueiras; Ranieri Coelho Salgado; Gabriel Jansen-Marques; Antonio Edson Rocha Oliveira; Jean Pierre Schatzmann Peron; Gustavo Cabral-Miranda; José Alexandre Marzagão Barbuto; Niels Olsen Saraiva Camara; Vera Lúcia Garcia Calich; Hans D Ochs; Antonio Condino-Neto; Katherine A Overmyer; Joshua J Coon; Joseph Balnis; Ariel Jaitovich; Jonas Schulte-Schrepping; Thomas Ulas; Joachim L Schultze; Helder I Nakaya; Igor Jurisica; Otávio Cabral-Marques Journal: Cells Date: 2022-03-01 Impact factor: 7.666
Authors: Josefine Persson; Björn Andersson; Suzanne van Veen; Mariëlle C Haks; Ogonna Obudulu; Sara Torkzadeh; Tom H M Ottenhoff; Nelly Kanberg; Magnus Gisslén; Lars-Magnus Andersson; Ali M Harandi Journal: Mol Immunol Date: 2022-03-04 Impact factor: 4.407